“We must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure,” Dr. J. Leonard Lichtenfeld.
“I hear many rejections that it is not possible to develop a drug so fast. But we did not say we will develop the drug and get its approval,” Morad continued. “We said we can treat and cure people.”
The team said that the company has presented and been subject to peer review, namely at three Drug Discovery Innovation Program conferences in Munich, Boston and Frankfurt. Major pharmaceutical companies attend those events, they said, including representatives from industry leaders Roche, Sanofi, Merck, Novartis, GSK and Bayer, for example.
AEBi maintained they have not published in a scientific journal – another point raised by critics – because they are a privately-owned company and are still in the process of generating final patents on their intellectual property. They said they have patents on their platform in the European Union, Israel and the United States.
The Post reached out to some 10 additional scientists and researchers, including hospitals and oncologists, most of whom did not want to comment on the record and felt that AEBi’s sweeping claims went too far.
But Dr. Moshik Cohen-Kutner, co-founder and CEO of Omnix Medical, said that while he does not know the company well enough to comment on whether they have a cure for cancer, “I do know that peptide-based drugs are very promising.”
“The technology of AEBi might be a cure for cancer because of the personalized route they are aiming for using selective peptides,” he continued. “It is only recently that the technology involving peptides has reached a point in which it is relatively easy to research. Peptides have the ability to cure human diseases.”
He told the Post that “robust and scientifically sound” projects may take one to two years to get from mice trials to human trials, providing there is adequate funding.
Nonetheless, as Lichtenfeld maintained in his blog post, “We hope this approach… bears fruit and is successful. At the same time, we must always offer a note of caution that the process to get this treatment from mouse to man is not always a simple and uncomplicated journey.”
SOURCE: THE JERUSALEM POST
